Table 2.
Characteristics of patients and hazard ratios (HR) (95% confidence interval [95%CI]) of mitotane in multivariate Cox regression model fitted for time of recurrence-free survival (RFS) and overall survival (OS), adjusted by age, gender, stage, positive surgical margins (PSMs), functional status and/or adjuvant radiation, etc.
| Reference | Year | Total No. | Age/ya | Male/% | Stage IV/%b | PSMs/%c | Function/% | Radiation/% | Mitotaned | RFS/HR(95%CI)e | OS /HR(95%CI)e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Berruti [16] | 2017 | 92 | 43 | 32 | 11 | - | 45 | 0 | 47 | 1/2.98(1.75-5.09) | 1/2.03(1.17-3.51) |
| Postlewait [27] | 2016 | 169g | 51 | 39 | 31 | 31 | 43 | 10 | 56 | 1.4(0.8-2.4) | 0.7(0.3-1.5) |
| Berruti [28] | 2014 | 524 | 45 | 39 | 0 | 0 | 52 | - | 251 | 0.66(0.53-0.83) | 0.82(0.60-1.10) |
| Grubbs [29] | 2010 | 215 | 46 | 35 | 4 | 27 | 55 | - | 19 | 1/1.96(1.07-3.61) | 1/1.58(0.75-3.31) |
| Fassnacht [30] | 2010 | 149 | 48 | 35 | 0 | 9 | - | 9 | 35 | 0.58(0.29-1.15) | 0.38(0.12-1.28) |
a Median or mean age of total population.
b Local advanced cases without distant metastasis.
c (R1+R2) / (R0+R1+R2) (R0 denotes microscopically negative margin; R1 denotes microscopically positive margin; R2 denotes grossly positive margin) in spite of Rx or data loss.
d Number of patients who received mitotane.
e HR of mitotane relative to nonmitotane. When a study provided HR of no mitotane relative to mitotane, it was recorded as 1/HR.